News

The administration of the first patient in the Phase III trial of autologous skeletal muscle-derived cells (ICEF15) for the treatment of fecal incontinence has been completed.

Innovacell will be featured in the Nikkei BP Bio-Healthcare Startup Overview 2023-2024.

The CEO and COO of Innovacell Inc. will present at the 30th CITIC CLSA Investors’ Forum.

First patient enrolled in Japan for the Phase III trial of autologous skeletal muscle-derived cells (ICEF15) targeting fecal incontinence.

[MEDIA Coverage] Answers News ‘Venture Visit Report

Domestic development of autologous skeletal muscle-derived cells (ICEF15) targeting fecal incontinence is finally underway.

The clinical trial application for a Phase III study of autologous skeletal muscle-derived cells (ICEF15) targeting fecal incontinence has been submitted.

The first administration to a patient in the Phase III trial of autologous skeletal muscle-derived cells (ICEF15) targeting fecal incontinence has been completed.

Innovacell has obtained the ‘Certification for Specific Cell Processing Products’ (Facility Number: FB8220003) from the Ministry of Health, Labour and Welfare based on the Act on Securing Safety etc. of Regenerative Medicine.

Results of the Phase IIb clinical trial of ICEF15 have been published in the American journal Clinical Gastroenterology and Hepatology.